DNA Chip Based Prognosis of Lung Cancer

Completed

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous and large cell lung cancer).

Key facts

Study ID

NCT00973427

Run by

Medical Prognosis Institute A/S

People needed

144

Starts

2008-06-01

Expected to finish

2014-09-01

Last updated by the study team

2015-09-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A histological diagnosis of primary NSCLC stage Ia
• Surgical removal of the tumor
• Age between 18 and 75 years
• Ability to understand and the willingness to sign a written informed consent document.

You may not qualify if…

• A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC stage Ib-IV after surgery.
• Adjuvant treatment with chemotherapy.
• Prior history of cancer in the past 5 years or breast cancer at any time.
• Life expectancy less than 3 years in the opinion of the investigator due to concurrent illnesses.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• Aarhus University Hospital — Aarhus, Denmark
• University of Copenhagen — Copenhagen, Denmark
• Odense University Hospital — Odense, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.